The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).
Jonathan A. Ledermann
Other Remuneration - AstraZeneca
Philipp Harter
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Charlie Gourley
Consultant or Advisory Role - Boehringer Ingelheim; Chugai Pharma; GlaxoSmithKline; Merck; Roche
Honoraria - Boehringer Ingelheim; Chugai Pharma; GlaxoSmithKline; Merck; Roche
Research Funding - AstraZeneca
Other Remuneration - Boehringer Ingelheim; Merck; PharmaMar; Roche
Michael Friedlander
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
Gordon J. S. Rustin
Consultant or Advisory Role - AstraZeneca
Clare L. Scott
Honoraria - Sanofi
Other Remuneration - AstraZeneca
Werner Meier
No relevant relationships to disclose
Ronnie Shapira-Frommer
No relevant relationships to disclose
Tamar Safra
No relevant relationships to disclose
Daniela Matei
No relevant relationships to disclose
Anitra Fielding
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Euan Macpherson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Brian Dougherty
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Juliane M. Jürgensmeier
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Maria Orr
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Ursula Matulonis
Research Funding - AstraZeneca